Literature DB >> 18612603

Ultrasensitive ELISA for measurement of human cytokine responses in primary culture.

William P Stefura1, J Darren Campbell, Renée Douville, Monique J Stinson, F Estelle Simons, Allan B Becker, Kent T HayGlass.   

Abstract

ELISAs offer excellent specificity and, once fully optimized, sensitivity that rivals that of bioassays. The major variables that need to be experimentally determined when developing an ELISA are the optimal number of fresh cells required per well, the optimal antigen concentrations for stimulation, period of culture, and the anticipated intensity of the response. In this chapter, we review the major factors to be considered in the development and application of ultrasensitive ELISAs to the analysis of human immune responses. We specify the conditions we have found to be optimal for quantifying a number of cytokines of demonstrated relevance to human immune regulation and discuss the major pitfalls inherent in this approach.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18612603     DOI: 10.1007/978-1-59745-366-0_10

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  10 in total

Review 1.  Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research.

Authors:  Xin Zhou; Maren S Fragala; Janet E McElhaney; George A Kuchel
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-09       Impact factor: 4.294

2.  Effects of storage conditions on the stability of serum CD163, NGAL, HMGB1 and MIP2.

Authors:  Jing Wang; Hai Hong Zhu; Ji Hua Xue; Shan Shan Wu; Zhi Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

3.  Are plasma IL-10 levels a useful marker of human clinical tolerance in peanut allergy?

Authors:  Larisa C Lotoski; F Estelle R Simons; Rishma Chooniedass; Joel Liem; Isha Ostopowich; Allan B Becker; Kent T HayGlass
Journal:  PLoS One       Date:  2010-06-17       Impact factor: 3.240

4.  TLR4 Asp299Gly and Thr399Ile polymorphisms: no impact on human immune responsiveness to LPS or respiratory syncytial virus.

Authors:  Renée N Douville; Yuriy Lissitsyn; Aaron F Hirschfeld; Allan B Becker; Anita L Kozyrskyj; Joel Liem; Nathalie Bastien; Yan Li; Rachel E Victor; Mehtab Sekhon; Stuart E Turvey; Kent T HayGlass
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

5.  Reovirus serotypes elicit distinctive patterns of recall immunity in humans.

Authors:  Renée N Douville; Ruey-Chyi Su; Kevin M Coombs; F Estelle R Simons; Kent T Hayglass
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

6.  A randomized controlled trial on the effects of goal-directed therapy on the inflammatory response open abdominal aortic aneurysm repair.

Authors:  Duane J Funk; Kent T HayGlass; Joshua Koulack; Greg Harding; April Boyd; Ryan Brinkman
Journal:  Crit Care       Date:  2015-06-10       Impact factor: 9.097

7.  Class II obese and healthy pregnant controls exhibit indistinguishable pro- and anti-inflammatory immune responses to Caesarian section.

Authors:  Caroline Graham; Mullein Thorleifson; William P Stefura; Duane J Funk; Kent T HayGlass
Journal:  Immun Inflamm Dis       Date:  2017-05-25

8.  Stability of pro- and anti-inflammatory immune biomarkers for human cohort studies.

Authors:  C Graham; R Chooniedass; W P Stefura; L Lotoski; P Lopez; A D Befus; A B Becker; K T HayGlass
Journal:  J Transl Med       Date:  2017-03-02       Impact factor: 5.531

9.  Elevated antigen-driven IL-9 responses are prominent in peanut allergic humans.

Authors:  Jungang Xie; Larisa C Lotoski; Rishma Chooniedass; Ruey-Chyi Su; F Estelle R Simons; Joel Liem; Allan B Becker; Jude Uzonna; Kent T HayGlass
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

10.  High Spinal Anesthesia Enhances Anti-Inflammatory Responses in Patients Undergoing Coronary Artery Bypass Graft Surgery and Aortic Valve Replacement: Randomized Pilot Study.

Authors:  Trevor W R Lee; Stephen Kowalski; Kelsey Falk; Doug Maguire; Darren H Freed; Kent T HayGlass
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.